Identify Top Producing Clones With Favorable Product Quality Attributes For Diverse Protein Therapeutics

Scientist are searching for solutions to meet a growing need for earlier information on quality and manufacturability of biomolecules. The range of novel and complex protein therapeutics currently entering industry bioproduction pipelines are growing and becoming more diverse. The fastest-growing and highest-producing clones may not secrete a product with the appropriate quality attributes. As a consequence, large numbers of clones must be expanded and characterized through repeated rounds of selection in order to maximize the probability of finding a cell line that makes high titers of manufacturable product.

Examine a workflow that provides a reduction in overall bioprocess costs, shortened timelines, improved cloning efficiencies and >99% monoclonality assurance.